 |
|
Costs and Health Consequences of Cholesterol Screening for Asymptomatic Older Americans
Alan M. Garber, MD, PhD;
Benjamin Littenberg, MD;
Harold C. Sox, Jr, MD;
Judith L. Wagner, PhD;
Michael Gluck, PhD
Arch Intern Med. 1991;151(6):1089-1095.
Abstract
To predict the consequences of cholesterol screening among elderly Americans who do not have symptoms of heart disease, we explore the cost implications of a cholesterol screening program, evaluate evidence linking hypercholesterolemia to coronary heart disease and mortality in the elderly, and describe the likely effects of therapy of hypercholesterolemia. According to our calculations, if all Americans 65 years of age and older adhered to a cholesterol screening program similar to the one proposed by the National Cholesterol Education Program, minimum annual expenditures for screening and treatment would be between $1.6 billion and $16.8 billion, depending on the effectiveness of diet and the cost of the medications used to treat hypercholesterolemia. There is no direct evidence that this program would lessen overall morbidity or extend the lives of elderly Americans.
(Arch Intern Med. 1991;151:1089-1095)
Author Affiliations
From the Division of General Internal Medicine, Stanford (Calif) University School of Medicine and Department of Veterans Affairs Medical Center, Palo Alto, Calif (Dr Garber); Department of Medicine, Dartmouth-Hitchcock Medical Center, Hanover, NH (Drs Littenberg and Sox); and Office of Technology Assessment, US Congress, Washington, DC (Drs Wagner and Gluck).
Footnotes
Accepted for publication November 19, 1990.
The views expressed herein are those of the authors and not necessarily those of the National Institute on Aging, the Department of Veterans Affairs, the Office of Technology Assessment, or the Henry J. Kaiser Family Foundation.
Reprint requests to 204 Junipero Serra Blvd, Stanford, CA 94305 (Dr Garber).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Analytic Tools for Public Health Decision Making
Owens
Med Decis Making 2002;22:S3-S10.
Impact of Major Cardiovascular Disease Risk Factors, Particularly in Combination, on 22-Year Mortality in Women and Men
Lowe et al.
Arch Intern Med 1998;158:2007-2014.
ABSTRACT
| FULL TEXT
Estimating the Benefits of Modifying Risk Factors of Cardiovascular Disease: A Comparison of Primary vs Secondary Prevention
Grover et al.
Arch Intern Med 1998;158:655-662.
ABSTRACT
| FULL TEXT
Treating Hyperlipidemia for the Primary Prevention of Coronary Disease: Are Higher Dosages of Lovastatin Cost-effective?
Perreault et al.
Arch Intern Med 1998;158:375-381.
ABSTRACT
| FULL TEXT
A Normative Analytic Framework for Development of Practice Guidelines for Specific Clinical Populations
Owens and Nease
Med Decis Making 1997;17:409-426.
ABSTRACT
Evaluating Cholesterol Screening: The Importance of Controlling for Regression to the Mean
Forrow et al.
Arch Intern Med 1995;155:2177-2184.
ABSTRACT
Dietitian Practices for Adult Outpatients With Hypercholesterolemia Referred by Physicians: The Minnesota Dietitian Survey
Elson et al.
Arch Fam Med 1994;3:1073-1080.
ABSTRACT
Cholesterol in the Elderly: Is It Important?
Hulley and Newman
JAMA 1994;272:1372-1374.
ABSTRACT
Eligibility for Cholesterol Referral in Community-dwelling Older Adults: The Cardiovascular Health Study
Manolio et al.
ANN INTERN MED 1992;116:641-649.
ABSTRACT
Guidelines for the Detection and Treatment of Elevated Serum Cholesterol: Which Is the Baby and Which Is the Bathwater?
Pearson
ANN INTERN MED 1991;115:324-326.
ABSTRACT
Should the Elderly Be Screened for Hypercholesterolemia?
Eisenberg
Arch Intern Med 1991;151:1063-1065.
ABSTRACT
|
